Curis Stock (NASDAQ:CRIS)


ForecastChart

Previous Close

$1.62

52W Range

$1.02 - $5.51

50D Avg

$1.68

200D Avg

$2.27

Market Cap

$20.25M

Avg Vol (3M)

$82.17K

Beta

3.86

Div Yield

-

CRIS Company Profile


Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

34

IPO Date

Aug 01, 2000

Website

CRIS Performance


Latest Earnings Call Transcripts


Q2 22Aug 05, 22 | 4:42 AM
Q1 22May 05, 22 | 6:55 PM
Q4 21Feb 24, 22 | 9:58 PM

Peer Comparison


TickerCompany
CRVSCorvus Pharmaceuticals, Inc.
RIGLRigel Pharmaceuticals, Inc.
AGENAgenus Inc.
LXRXLexicon Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
SLRXSalarius Pharmaceuticals, Inc.
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks